As of Q4'25 (2025-12-28), Johnson & Johnson reported revenue of $24.6B, with year-over-year revenue growth reaching 9.1%. This marks the highest revenue and YoY growth rate observed in the period covered. From Q1'23 to Q4'25, JNJ’s revenue displayed significant volatility, with a notable dip to $13.5B in Q4'23, followed by a strong recovery and steady growth through 2024 and 2025. The YoY growth rate turned sharply negative in late 2023 but rebounded strongly in 2024, peaking at 66.4% in Q4'24 before stabilizing at high single-digit growth rates in 2025. This trend suggests a period of disruption followed by robust recovery and sustained momentum into the latest quarter.